Advanced Liquid Technology has entered into a deal with Grow Group that will see its cannabis medicine technology enter the European market.
The deal between Advanced Liquid Technology (ALT) and Grow Group will market and distribute ALT’s proprietary, fast-acting, liquid medical cannabis products across Europe.
Grow Group’s CEO Ben Langley said: “GROW’s mission is to bring medical cannabis products to all patients who need it. We strive to constantly improve and innovate on our product offering.
“With our leading position and unique experience we are very confident that with ALT’S new mode of administration using liquid medical cannabis we are going to make another leap forward in providing patients with the best products and solutions for their symptom management.”
New products for European patients
The products will benefit European patients with rapid on-set effects within five to 15 minutes alongside improved absorption efficiency, as well as allowing patients to titrate their dose accordingly. They will also benefit doctors by enabling them to recommend precise doses of cannabinoids to patients based on their individual need for relief from ailments.
The emulsion technology creates unique flavour neutral, zero calories, sugar-free, vegan, keto and paleo-friendly, water-compatible nanoemulsions. The products are kinetically stable with an incredibly small particle size, allowing for more effective delivery of cannabinoids to the user compared to tinctures and other ingestible products, and can be consumed directly or with another drink.
ALT’s CEO, Robert Davis, commented, “We are honoured to partner with Grow in bringing ALT’s completely differentiated brand and liquid medical cannabis technologies to the European medical markets.
“After successfully launching ALT into California in December of 2020, we are excited to expand internationally, our first step in becoming a global brand. ALT’s mission is to Enhance Human Potential and we will do so, one patient at a time, through the power of our liquid cannabis platform.”
ALT plans to have a range of EU GMP-certified liquid medical cannabis products available for patients in the UK and Germany by early 2022, who will have access to the products by obtaining prescriptions through private practice or national health services.
Bar Capital Global introduced and advised both ALT and Grow on this groundbreaking relationship and will continue to assist in the successful launch of the products.
[activecampaign form=31]
